CNS Edema Opportunity Remedy Pharmaceuticals targets life threatening brain edema with CIRARA intravenous glyburide, addressing a major unmet need in neurocritical care and in tumor brain management. The opportunity spans stroke, brain injury, and related conditions, creating multiple avenues for hospital programs, centers of excellence, and academic partnerships to adopt a novel therapy.

Clinical Validation Momentum Recent conference presentations showcased efficacy signals from late stage studies in large hemispheric infarction, strengthening the case for CIRARA as a potential standard of care in neurocritical settings. This momentum supports targeted outreach to health systems, payers, and clinical networks for trials, access pathways, and reimbursement discussions.

Market Access Potential The CNS edema opportunity includes neurocritical care units, stroke centers, and brain tumor programs, offering multiple paths to early adoption and scalable deployment. Proximity to New York City enables engagement with leading academic medical centers and regional health networks for pilots and broader rollout.

Strategic Partnerships As a small, focused company with early revenue, Remedy can pursue licensing, co development, or distribution alliances with larger pharma or specialty biotech to accelerate market access and reimbursement. Collaborations with hospitals, CROs, and industry partners can accelerate trial execution, evidence generation, and real world data collection.

Commercial Readiness To drive adoption, prioritize payer engagement, pricing strategies, and evidence generation, while building a network of key opinion leaders and centers of excellence in high burden settings. Early alignment with clinical champions and health systems will help accelerate uptake of CIRARA in eligible patient populations.